DUBLIN–(BUSINESS WIRE)–The “Global
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech
2014-2019” report has been added to ResearchAndMarkets.com’s
This report provides a detailed understanding and analysis of how, why
and what terms companies enter preclinical stage partnering deals. These
deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
This report provides details of the latest preclinical agreements
announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered – contract documents provide this insight where press releases
and databases do not.
This report contains a comprehensive listing of over 2,000 preclinical
stage partnering deals announced since 2014 including financial terms,
where available, including links to online deal records of actual
preclinical partnering deals as disclosed by the deal parties. In
addition, where available, records include contract documents as
submitted to the Securities Exchange Commission by companies and their
Contract documents provide the answers to numerous questions about a
prospective partner’s flexibility on a wide range of important issues,
many of which will have a significant impact on each party’s ability to
derive value from the deal.
The initial chapters of this report provide an orientation of
preclinical stage deal making and business activities. Chapter 1
provides an introduction to the report, whilst chapter 2 provides an
overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and
deal structure including numerous case studies. Chapter 4 provides an
overview of the various payment strategies used in preclinical stage
Chapter 5 provides a review of preclinical stage deal making since 2014.
Deals activity is reviewed by year, stage of development at signing,
therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of preclinical stage payment
terms including headline, upfront, milestone and royalty rates.
Chapter 7 provides a review of the leading preclinical stage deal by
headline value. Each deal title links via Current Agreements deals and
alliances database to an online version of the full deal record, and
where available, the actual contract document, providing easy access to
each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 50 most active
preclinical stage dealmaker companies. Each deal title links via Current
Agreements deals and alliances database to an online version of the full
deal record, and where available, the actual contract document,
providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical
stage partnering deals signed and announced since 2014, where a contract
document is available in the public domain.
Chapter 10 provides a comprehensive directory of preclinical stage
partnering deals since 2014.
The report includes deals announced by hundreds of life science
companies including big pharma such as Abbott, Abbvie, Actavis, Amgen,
Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai,
Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan,
Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant,
amongst many others.
The report also includes numerous tables and figures that illustrate the
trends and activities in preclinical stage partnering and deal making
In addition, a comprehensive appendix of all preclinical deals since
2014 is provided organized by partnering company A-Z, deal type, therapy
focus and technology type. Each deal title links via Weblink to an
online version of the deal record and where available, the contract
document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of preclinical stage products and compounds.
- In-depth understanding of preclinical stage deal trends since 2014
- Access to headline, upfront, milestone and royalty data
Analysis of the structure of preclinical stage agreements with
numerous real life case studies
Insight into the terms included in a preclinical stage agreement,
together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal
terms for partner companies
Global Preclinical Stage Partnering Terms and Agreements in Pharma and
Biotech 2014-2019 is intended to provide the reader with an in-depth
understanding and access to preclinical stage deal trends and structure
of deals entered into by leading companies worldwide.
Global Preclinical Stage Partnering Terms and Agreements in
Pharma and Biotech 2014-2019 includes:
Trends in preclinical stage dealmaking in the biopharma industry since
- Analysis of preclinical stage deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life preclinical stage deals
- Access to over 2,000 preclinical stage deals
- The leading preclinical stage deals by value since 2014
- Most active preclinical stage dealmakers since 2014
- The leading preclinical stage partnering resources
In Global Preclinical Stage Partnering Terms and Agreements in
Pharma and Biotech 2014-2019, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal
record and where available, the contract document, providing easy access
to each contract document on demand.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma
and Biotech 2014-2019 report provides comprehensive access to available
deals and contract documents for over 2,000 preclinical stage deals.
Analyzing actual contract agreements allows assessment of the
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sub-licensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or
deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
For more information about this report visit https://www.researchandmarkets.com/research/zpb8n4/global?w=4
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900